Good stuff, Jake. I just want to throw in my earlier experience being all-in on a company whose only source of funding for trials was the government. That other company (SIGA) is doing well now, but it was and dependent on grants from BARDA, the NIH, and the DoD. Progress was slow. The govt had to respond to protests from a rival company. Eight protests. It took years to get the contract that the govt agency WANTED to give SIGA.

I don't know why Merck is trying to find combos despite the fact that it that won't extend Keytruda's patent, assuming Ohm is right.

Maybe it's just a way of finding the Aaron Rodgers (or indeed Jordan Love) waiting on the sidelines, as you suggest.

Maybe if Key + Leron works well in a Merck-funded trial, only Merck will know how much of that is down to Leron, so they can lowball CYDY with a BO. Maybe it will be easier to get patients to try Leron if it's paired with Keytruda. I don't know. I'd really like to know.

Back to the more important stuff:

Biloxi, I think Ohm was kidding.

MGK, as I've written to you before, Evil is right: keep your pieces shorter, and it will expand and please your audience. And please don't state something as a fact when it's conjecture or estimate (example: the inflammation trial was abandoned because it was going to cost $10 M, and we couldn't afford it). Do those two things and you will be even more highly esteemed as a poster.